Public-domain · open source
OpenJurist

R.I. Gen. Laws § 5-19.3-5

Prohibition on certain discriminatory actions by a pharmaceutical manufacturer, agent, or affiliate of such manufacturer related to 340B entities

Known as the Defending Affordable Prescription Drug Costs Act

The act spans §§ 5–5 (9 sections).

P.L. 2025, ch. 288, § 1, effective October 1, 2025; P.L. 2025, ch. 290, § 1, effective October 1, 2025.

(a) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not deny, restrict, prohibit, or otherwise interfere with, either directly or indirectly, the acquisition of a 340B drug by, or delivery of a 340B drug to, a pharmacy that is under contract with a 340B covered entity and is authorized under such contract to receive and dispense 340B drugs on behalf of the covered entity unless such receipt is prohibited by the United States department of health and human services.

(b) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not interfere with a 340B contract pharmacy that is actively contracted with a 340B covered entity.

(c) A pharmaceutical manufacturer, agent, or affiliate of such manufacturer shall not impose additional terms or limitations not required by federal law as a condition of 340B participation.

Official source: Rhode Island General Assembly. Reproduced from public-domain Rhode Island statutes; confirm against the official source for the current text. Not legal advice.